Loading organizations...
Founded in 2017 by David R. Liu, Feng Zhang, and J. Keith Joung, Beam Therapeutics is a Cambridge, Massachusetts-based biotechnology company developing precision genetic medicines using proprietary base editing technology to make single-base changes in DNA and RNA. The clinical-stage firm focuses on severe genetic conditions, hematology, and immunology, advancing lead programs like BEAM-101 for sickle cell disease. Operating as a publicly traded entity with a market capitalization of approximately $2 billion, the company employs over 300 people following a 20% workforce reduction in 2023 to extend its cash runway. Beam Therapeutics raised $180 million in its 2020 initial public offering after securing early backing from F-Prime Capital Partners and ARCH Venture Partners. The enterprise generates additional capital through strategic research collaborations and technology licensing agreements with major pharmaceutical corporations, including Pfizer and Eli Lilly.
Beam Therapeutics has raised $222.0M across 2 funding rounds.
Beam Therapeutics has raised $222.0M in total across 2 funding rounds.
Beam Therapeutics has raised $222.0M across 2 funding rounds. Most recently, it raised $135.0M Series B in March 2019.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 6, 2019 | $135M Series B | — | Altitude Life Science Ventures, ARCH Venture Partners, Cormorant Asset Management, Eight Roads Ventures, F Prime Capital, GV, Omega Funds, Redmile Group | Announced |
| May 14, 2018 | $87M Series A | Kristina Burow, Stephen Knight | — | Announced |
Beam Therapeutics has raised $222.0M in total across 2 funding rounds.
Beam Therapeutics's investors include Altitude Life Science Ventures, ARCH Venture Partners, Cormorant Asset Management, Eight Roads Ventures, F-Prime Capital, Google Ventures, Omega Funds, Redmile Group, Kristina Burow, Stephen Knight.
